Q-omics provides the consensus-scored BORCS8-MEF2B profile across patient tissues and cancer cell-line models. BORCS8-MEF2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, BORCS8-MEF2B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, BORCS8-MEF2B RNA expression shows 18,605 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where BORCS8-MEF2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BORCS8-MEF2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BORCS8-MEF2B survival associations across molecular data types. BORCS8-MEF2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BORCS8-MEF2B RNA expression–survival associations across cancer types. High BORCS8-MEF2B expression shows unfavorable associations in KICH, ACC, KIRC, COAD and LIHC, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for BORCS8-MEF2B RNA expression.
This table summarizes BORCS8-MEF2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BORCS8-MEF2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BORCS8-MEF2B shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, KIRP, LIHC and CHOL. The KIRC box plot shows higher BORCS8-MEF2B RNA expression in tumor versus normal tissue (log2 FC = +0.236, t-test p < 0.001).
This table shows molecular features associated with BORCS8-MEF2B in patient tissues and cancer cell lines. In patient samples, BORCS8-MEF2B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BORCS8-MEF2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER.
